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Background: The clinical utility of intracoronary abciximab (IC abcx) and thrombus aspiration in pts with STEMI undergoing primary PCI remains 
controversial.
methods: In the INFUSE-AMI trial, 452 pts at 37 sites in 6 countries presenting within 4 hours of STEMI due to proximal or mid LAD occlusion 
undergoing primary PCI with bivalirudin anticoagulation were randomized to bolus IC abcx delivered locally at the infarct lesion site via the ClearWay 
RX infusion catheter vs. no abcx, and to thrombus aspiration with the Export catheter vs. no aspiration. The primary efficacy endpoint was infarct size 
(ISz) at 30 days measured by cardiac MRI. Secondary efficacy endpoints included ST-segment resolution (STR), angiographic perfusion (TIMI flow 
and blush), and clinical outcomes with follow-up through 1 year.
results: At 30 days, IC abcx compared to no abcx reduced median [IQR] ISz (15.1% [6.8%, 22.7%] vs. 17.9% [10.3%, 25.4%], P=0.03), absolute 
infarct mass and abnormal wall motion score. Conversely, 30-day ISz (17.0% [9.0%, 22.8%] vs. 17.3% [7.1%, 25.5%] and other measures of 
myonecrosis were similar between aspiration and no aspiration. The rates of TIMI flow, blush, STR and 30-day clinical events were not significantly 
different between the randomized groups.
conclusions: The 6-month and 1-year results from the INFUSE-AMI trial will be presented for the first time at ACC 2013, and will provide insights 
into the relationship between randomization strategy, ISz at 30 days and other reperfusion biomarkers to late clinical outcomes in pts with large 
anterior STEMI undergoing primary PCI.
